Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Etoricoxib
Drug ID BADD_D00856
Description Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
Indications and Usage For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Marketing Status approved; investigational
ATC Code M01AH05
DrugBank ID DB01628
KEGG ID D03710
MeSH ID D000077613
PubChem ID 123619
TTD Drug ID D09MGR
NDC Product Code 42765-006; 68554-0053
UNII WRX4NFY03R
Synonyms Etoricoxib | MK 0663 | MK-0663 | MK0663 | Arcoxia | L-791456 | L 791456 | L791456
Chemical Information
Molecular Formula C18H15ClN2O2S
CAS Registry Number 202409-33-4
SMILES CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinusitis22.07.03.007; 11.01.13.005--
Sjogren's syndrome06.08.02.011; 15.06.01.015; 10.04.04.009; 07.06.01.010--Not Available
Skin disorder23.03.03.007--Not Available
Skin infection23.11.04.007; 11.01.12.003--
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Stomatitis07.05.06.005--
Sunburn23.03.09.007; 12.05.02.001--Not Available
Tendonitis15.07.01.003; 12.01.07.007--Not Available
Tenosynovitis15.07.01.004--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinea pedis23.11.03.012; 11.03.08.004--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue oedema10.01.05.008; 23.04.01.009; 07.14.02.007--Not Available
Toothache07.09.06.001--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Traumatic arthropathy15.01.01.013; 12.04.03.006--Not Available
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vision blurred17.17.01.010; 06.02.06.007--
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages